8-K Announcements
6Material company update
Mar 25, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Feb 25, 2026·SEC
Tevogen Bio Holdings Inc.(TVGN)Earnings, Financials & Key Ratios
TVGN•NASDAQ
Price updated Jun 19, 2026
AboutTevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.Show more
- Revenue$0
- EBITDA-$53M-528.0%
- Net Income-$10M+83.3%
- EPS (Diluted)-0.09-23300.0%
TVGN Key Insights
Tevogen Bio Holdings Inc. (TVGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 11.3% through buybacks
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TVGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TVGN Price & Volume
Tevogen Bio Holdings Inc. (TVGN) stock price & volume — 10-year historical chart
Loading chart...
TVGN Growth Metrics
Tevogen Bio Holdings Inc. (TVGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-612.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM47.61%
Return on Capital
10 Years-892.72%
5 Years-892.72%
3 Years-1306.05%
Last Year-
TVGN Recent Earnings
Tevogen Bio Holdings Inc. (TVGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (67%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$1.61+39.0%
$2.64
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$1.20+20.0%
$1.50
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.03+50.7%
$0.06
Rev
—
—
Q3 2025
Aug 19, 2025Metric
Actual
Est
EPS
$0.03+40.0%
$0.05
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.61vs $2.64+39.0% | — |
| Q2 2026 | Mar 31, 2026 | $1.20vs $1.50+20.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.03vs $0.06+50.7% | — |
| Q3 2025 | Aug 19, 2025 | $0.03vs $0.05+40.0% | — |
Based on last 12 quarters of dataView full earnings history →
TVGN Peer Comparison
Tevogen Bio Holdings Inc. (TVGN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 DYAI | 28.5M | 0.78 | -3.40 | -64.74% | -245.12% | -10.05% | 4.11 | |
 VXRT | 133.33M | 0.55 | 7.87 | 7.27% | 14.51% | 61.43% | 0.10 |
Compare TVGN vs Peers
Tevogen Bio Holdings Inc. (TVGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TVGN Income Statement
Tevogen Bio Holdings Inc. (TVGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 378.36K | 403.58K | 526.96K |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -378.36K▲ 0% | -403.58K▼ 6.7% | -526.96K▲ 0% |
Gross Margin % | - | - | - | - | - |
Gross Profit Growth % | - | - | - | -6.67% | - |
Operating Expenses | 4.62M | 953.08K | 8.46M | 53.16M | 30.37M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 1.66M | 953.08K | 4.06M | 22.13M | 18.52M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 2.96M | 0 | 4.4M | 31.03M | 11.84M |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
Operating Income | -4.62M▲ 0% | -953.08K▲ 79.4% | -8.84M▼ 827.8% | -53.56M▼ 505.7% | -30.89M▲ 0% |
Operating Margin % | - | - | - | - | - |
Operating Income Growth % | - | 79.36% | -827.83% | -505.73% | - |
EBITDA | -4.61M | 4.41M | -8.46M | -53.16M | -30.37M |
EBITDA Margin % | - | - | - | - | - |
EBITDA Growth % | - | 195.65% | -292.01% | -528.03% | 33.71% |
D&A (Non-Cash Add-back) | 9.38K | 0 | 378.36K | 403.58K | 526.96K |
EBIT | -15M | 4.41M | -59.27M | -13.54M | -30.9M |
Net Interest Income | -598.5K | 0 | -256.03K | -184.04K | -140.74K |
Interest Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 598.5K | 0 | 256.03K | 184.04K | 140.74K |
Other Income/Expense | -10.98M | 5.36M | -51.63M | 39.84M | -148.88K |
Pretax Income | -15.6M▲ 0% | 4.41M▲ 128.3% | -60.48M▼ 1471.9% | -13.73M▲ 77.3% | -31.04M▲ 0% |
Pretax Margin % | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
Net Income | -15.6M▲ 0% | 4.41M▲ 128.3% | -60.48M▼ 1471.9% | -10.11M▲ 83.3% | -30.85M▲ 0% |
Net Margin % | - | - | - | - | - |
Net Income Growth % | - | 128.26% | -1471.89% | 83.28% | -612.87% |
Net Income (Continuing) | -15.6M | 4.41M | -60.48M | -13.73M | -31.04M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.33▲ 0% | 0.04▲ 111.1% | -0.00▼ 101.1% | -0.09▼ 23300.0% | -0.16▲ 0% |
EPS Growth % | - | 111.12% | -101.09% | - | 47.61% |
EPS (Basic) | -0.33 | 0.04 | -0.00 | -0.09 | - |
Diluted Shares Outstanding | 47.93M | 120M | 165.42M | 146.67M | 196.03M |
Basic Shares Outstanding | 47.93M | 120M | 165.42M | 146.67M | 196.03M |
Dividend Payout Ratio | - | - | - | - | - |
TVGN Balance Sheet
Tevogen Bio Holdings Inc. (TVGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 7.17M | 5.84M | 1.72M | 2.36M | 2.12M |
Cash & Short-Term Investments | 7.12M | 5.48M | 1.05M | 1.28M | 1.04M |
Cash Only | 7.12M | 5.48M | 1.05M | 1.28M | 1.04M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 158.82K | 158.82K |
Days Sales Outstanding | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 53.96K | 0 | 0 | 919.09K | 925.82K |
Total Non-Current Assets | 485.27K | 1.9M | 3.78M | 1.1M | 2.37M |
Property, Plant & Equipment | 142.62K | 1.31M | 928.51K | 524.93K | 1.62M |
Fixed Asset Turnover | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 351.92M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -351.57M | 594.88K | 2.85M | 575.84K | 756.81K |
Total Assets | 7.66M▲ 0% | 7.74M▲ 1.1% | 5.51M▼ 28.9% | 3.46M▼ 37.1% | 4.49M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x |
Asset Growth % | - | 1.05% | -28.86% | -37.12% | 17.71% |
Total Current Liabilities | 667.94K | 1.96M | 85.48M | 9.04M | 6.74M |
Accounts Payable | 378K | 865.91K | 3.42M | 5.2M | 3.31M |
Days Payables Outstanding | - | - | 3.3K | 4.7K | 3.02K |
Short-Term Debt | 0 | 0 | 80.71M | 1.65M | 1.65M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 45.27K | 237.6K | 120.15K | 403.23K | 240.3K |
Current Ratio | 10.74x | 2.98x | 0.02x | 0.26x | 0.31x |
Quick Ratio | 10.74x | 2.98x | 0.02x | 0.26x | 0.31x |
Cash Conversion Cycle | - | - | - | - | - |
Total Non-Current Liabilities | 23.48M | 39.73M | 14.45M | 1.09M | 5.58M |
Long-Term Debt | 23.48M | 39.3M | 14.22M | 1M | 4.4M |
Capital Lease Obligations | 0 | 432.73K | 234.86K | 5.8K | 2.33M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 87.18K | 29.77K |
Total Liabilities | 24.15M | 41.69M | 99.93M | 10.14M | 12.32M |
Total Debt | 23.48M | 40.01M | 95.42M | 2.89M | 7.53M |
Net Debt | 16.36M | 34.52M | 94.37M | 1.6M | 6.49M |
Debt / Equity | - | - | - | - | -0.96x |
Debt / EBITDA | - | 9.08x | - | - | -0.25x |
Net Debt / EBITDA | - | 7.83x | - | - | -0.21x |
Interest Coverage | -7.72x | - | -34.54x | -291.05x | -219.56x |
Total Equity | -16.49M▲ 0% | -33.95M▼ 105.9% | -94.43M▼ 178.1% | -6.67M▲ 92.9% | -7.82M▲ 0% |
Equity Growth % | - | -105.91% | -178.13% | 92.93% | 9.26% |
Book Value per Share | -0.34 | -0.28 | -0.57 | -0.05 | -0.04 |
Total Shareholders' Equity | -16.49M | -33.95M | -94.43M | -6.67M | -7.82M |
Common Stock | 63.88K | 61.88K | 12K | 17.8K | 19.74K |
Retained Earnings | -17.14M | -39.18M | -99.66M | -113.39M | -134.98M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
TVGN Cash Flow Statement
Tevogen Bio Holdings Inc. (TVGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -5.27M | -8.66M | -8.17M | -12M | -13.19M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | -64.09% | 5.6% | -46.84% | -109.95% |
Net Income | -15.6M | -22.04M | -60.48M | -13.73M | -30.85M |
Depreciation & Amortization | 9.38K | 230.82K | 378.36K | 403.58K | 262.77K |
Stock-Based Compensation | 582.41K | 4.58M | 0 | 40.76M | 10.53M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 10.98M | 8.67M | 51.63M | -39.43M | 10.3M |
Working Capital Changes | -1.25M | -96.92K | 293.2K | -5.49K | -3.44M |
Change in Receivables | 0 | 0 | -267K | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.09M | 0 | 1.11M | 1.69M | -959.94K |
Cash from Investing | -109.73K | -479.04K | -133K | 0 | 0 |
Capital Expenditures | -109.73K | -479.04K | -133K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 12.5M | 7.5M | 3.87M | 12.23M | 11.9M |
Debt Issued (Net) | 12.5M | 7.5M | 4M | 1M | 3.4M |
Equity Issued (Net) | 0 | 0 | -1000K | 1000K | 3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -342.98M | 0 | 0 |
Other Financing | 0 | 0 | 342.86M | 229.33K | 1.5M |
Net Change in Cash | 7.12M▲ 0% | -1.63M▼ 123.0% | -4.43M▼ 171.1% | 230.6K▲ 105.2% | -1.29M▲ 0% |
Free Cash Flow | -5.38M▲ 0% | -9.13M▼ 69.6% | -8.3M▲ 9.1% | -12M▼ 44.5% | -13.19M▲ 0% |
FCF Margin % | - | - | - | - | - |
FCF Growth % | - | -69.65% | 9.09% | -44.49% | -20.75% |
FCF per Share | -0.11 | -0.08 | -0.05 | -0.08 | -0.07 |
FCF Conversion (FCF/Net Income) | 0.34x | -1.96x | 0.14x | 1.19x | 0.43x |
Interest Paid | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 |
TVGN Key Ratios
Tevogen Bio Holdings Inc. (TVGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | 389.21% |
Return on Invested Capital (ROIC) | -322.18% | -2597.18% | - | 667.24% |
Debt / Equity | - | - | - | -0.96x |
Interest Coverage | - | -34.54x | -291.05x | -219.56x |
FCF Conversion | -1.96x | 0.14x | 1.19x | 0.43x |
Related:TVGN Dividend History·TVGN Revenue History·TVGN Price History·TVGN P/E History·TVGN Financial Ratios·TVGN Institutional Holders
TVGN SEC Filings & Documents
Tevogen Bio Holdings Inc. (TVGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
TVGN Frequently Asked Questions
Tevogen Bio Holdings Inc. (TVGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tevogen Bio Holdings Inc. (TVGN) grew revenue by 0.0% over the past year. Growth has been modest.
Tevogen Bio Holdings Inc. (TVGN) reported a net loss of $30.8M for fiscal year 2024.
Dividend & Returns
Tevogen Bio Holdings Inc. (TVGN) had negative free cash flow of $13.2M in fiscal year 2024, likely due to heavy capital investments.